# Magnevist® Injection Enhanced MRA Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Aortic Arch and Cerebral Branches

> **NCT00310609** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 123 (actual)

## Conditions studied

- Cardiovascular Abnormalities

## Interventions

- **DRUG:** Gadopentetate dimeglumine (Magnevist)

## Key facts

- **NCT ID:** NCT00310609
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** —
- **Final completion:** 2004-10
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2014-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00310609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00310609, "Magnevist® Injection Enhanced MRA Compared to Non Contrast MRA for the Detection of Structural Abnormalities of the Aortic Arch and Cerebral Branches". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00310609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*